Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05297903 · ClinicalTrials.gov registry record · Phase 2
XmAb20717 in Advanced Biliary Tract Cancers
A Phase 2 study of Biliary Tract Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT05297903 is a Phase 2 study of Biliary Tract Cancer that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 27 participants, below the 239-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05297903, a Phase 2 study of Biliary Tract Cancer, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-arm, phase II clinical trial to evaluate the efficacy of XmAb20717 in patients with advanced biliary tract cancers who have progressed on, or were intolerant of, a gemcitabine-based chemotherapy regimen.
Conditions Studied
Interventions
- DRUG XmAb20717
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-04-11 |
| Est. Completion | 2026-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05297903
The ClinicalTrials.gov registry entry for NCT05297903 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Biliary Tract Cancer appearing as the primary indexed condition, and to 1 intervention - of which XmAb20717 is the first listed.
NCT05297903 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05297903 about?
NCT05297903 is a clinical study titled "XmAb20717 in Advanced Biliary Tract Cancers". This is a single-arm, phase II clinical trial to evaluate the efficacy of XmAb20717 in patients with advanced biliary tract cancers who have progressed on, or were intolerant of, a gemcitabine-based chemotherapy regimen.
What is the current status of trial NCT05297903?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2022-04-11. Estimated completion is 2026-12-02.
What conditions does trial NCT05297903 study?
This clinical trial studies the following conditions: Biliary Tract Cancer.
What interventions are being tested in trial NCT05297903?
The interventions under investigation include: XmAb20717 (DRUG).
Who is sponsoring clinical trial NCT05297903?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05297903 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biliary Tract Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
-
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
RECRUITING · Phase 2
-
Ligufalimab and Cadonilimab in Advanced Liver Cancers
RECRUITING · Phase 2
-
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.